Company Analysis

uniQure N.V. (QURE)

Nasdaq: QURE · Pharmaceutical Preparations · Amsterdam · filing with the SEC since 2013
Grade4.1
◀ Past 5.1● Present 4.1▶ Future 3.5
1 est.

Who runs uniQure N.V.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Kapusta Matthew C
CEO, Managing Director. First filing Jan 2017, latest Jul 7, 2026, 55 filings in all.
Officers reporting now
6
of 12 people with a filing in the last fifteen months
Directors reporting now
6
28 people on the record since 2017
Officerssales are open-market, Nov 10, 2025 to Nov 10, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Abi-Saab WalidChief Medical OfficerOct 2023Nov 3, 20267 · $2.6M
Kapusta Matthew CCEO, Managing DirectorJan 2017Jul 7, 202616 · $12.9M
Potts JeannetteChief Legal OfficerJun 2023Jun 17, 20263 · $300,000
Gut RobertChief Medical OfficerJun 2018Jun 12, 20267 · $900,000
O'Keefe KylieChief Customer & Strat OfficerMar 2026Jun 12, 20261 · $400,000
Klemt ChristianChief Financial OfficerAug 2017Mar 6, 20263 · $400,000
Directorssales are open-market, Nov 10, 2025 to Nov 10, 2026
NameRoleFirst filingLatest filingSales, 12 months
Meek David D.directorJun 2018Nov 10, 20262 · $200,000
Kaye JackdirectorJan 2017Jul 2, 20266 · $1.5M
Balachandran MadhavandirectorSep 2017Jun 22, 20265 · $900,000
Jacques Rachelle SuzannedirectorOct 2021Jun 12, 20261 · $100,000
Post Leonard EdirectorJun 2020Jun 12, 20261 · $100,000
Springhorn Jeremy P.directorSep 2017Jun 12, 20261 · $100,000
Earlier names on the record18, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton QURE · research, not advice